CliffBio
small molecule

EPTIFIBATIDE

EPTIFIBATIDE

Loss of exclusivity—loss of exclusivity
CompanyBaxter Healthcare Corp →See this company's full patent-cliff portfolio

Drug detail

Brand nameEPTIFIBATIDE
Active ingredientEPTIFIBATIDE
Strength2MG/ML
Dosage formINJECTABLE
RouteINJECTION
ModalitySmall molecule
FDA approvalNovember 2018
Marketing statusDISCN

More from Baxter Healthcare Corp

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.